secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2026-06-04T20:05:16+00:00
Accession:  0001193125-26-257365
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics stockholders approve doubling of authorized shares to 400M and 8M share increase in stock plan
--------------------------------------------------------------------------------

- Elected Michael Heffernan as Class I director for a term expiring at the 2029 annual meeting.
- Ratified Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
- Advisory vote approved compensation of named executive officers with 98.1M for vs. 2.0M against.
- Approved Amended and Restated 2019 Stock Incentive Plan, increasing shares available by 8M.
- Approved Certificate of Amendment to double authorized common stock from 200M to 400M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/trvi-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer